The New England Journal of Medicine

Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease

We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signaling.
Nasdaq

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today ...
News Medical

SARS-CoV-2 infection leads to higher IgA levels in breast milk than vaccination

Compared to infant formula, breastmilk contains antibodies that offer passive immunity to the infant against many communicable diseases. A recent paper in the journal iScience explores the presence ...
Nasdaq

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) ...
Seeking Alpha

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA ® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG ...
Seeking Alpha

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as ...